On Jul 1, 2021 TCR Cure closed a Series C round and raised $50,000,000.

About the company: TCR Cure is located at China, Asia. “TCRCure Biopharma Ltd. aims to develop next generation cancer immunotherapies that control tumor progression, convert cancers to manageable chronic diseases, and eventually lead to a cure.

TCRCure is a leading international company focused on streamlined biotechnology development including high throughput antigen-specific TCR cloning, industry scale virus production, T cell genetic engineering, and immune cell manufacturing.”

Company website: www.tcrcure.com/